DE10299037I1 - 2-Zykloakyl-oder Arylalkylderivate von nicht-Saeure Zyklopentane-Heptanoic-Saeure - Google Patents

2-Zykloakyl-oder Arylalkylderivate von nicht-Saeure Zyklopentane-Heptanoic-Saeure

Info

Publication number
DE10299037I1
DE10299037I1 DE2002199037 DE10299037C DE10299037I1 DE 10299037 I1 DE10299037 I1 DE 10299037I1 DE 2002199037 DE2002199037 DE 2002199037 DE 10299037 C DE10299037 C DE 10299037C DE 10299037 I1 DE10299037 I1 DE 10299037I1
Authority
DE
Germany
Prior art keywords
cycloalkyl
arylalkyl
derivatives
heptanoic acid
cyclopentane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE2002199037
Other languages
English (en)
Other versions
DE10299037I2 (de
Inventor
David Woodward
Steven Andrews
Rober Burk
Michael Garst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25487188&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE10299037(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DE10299037I1 publication Critical patent/DE10299037I1/de
Publication of DE10299037I2 publication Critical patent/DE10299037I2/de
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00—Compounds containing azido groups
    • C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/08—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated
    • C07C247/10—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/36—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/21—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a non-condensed ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
DE2002199037 1992-09-21 1993-09-09 2-Zykloalkyl-oder arylalkyl-derivate von nicht-s{ure, zyklopentane-heptanoic-s{ure. Active DE10299037I2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/948,056 US5352708A (en) 1992-09-21 1992-09-21 Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
PCT/US1993/008472 WO1994006433A1 (en) 1992-09-21 1993-09-09 Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents

Publications (2)

Publication Number Publication Date
DE10299037I1 true DE10299037I1 (de) 2003-02-20
DE10299037I2 DE10299037I2 (de) 2004-09-23

Family

ID=25487188

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69331233.5T Expired - Lifetime DE69331233C5 (de) 1992-09-21 1993-09-09 2-zykloalkyl-oder arylalkyl-derivate von nicht-säure, zyklopentane-heptanoic-säure
DE2002199037 Active DE10299037I2 (de) 1992-09-21 1993-09-09 2-Zykloalkyl-oder arylalkyl-derivate von nicht-s{ure, zyklopentane-heptanoic-s{ure.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69331233.5T Expired - Lifetime DE69331233C5 (de) 1992-09-21 1993-09-09 2-zykloalkyl-oder arylalkyl-derivate von nicht-säure, zyklopentane-heptanoic-säure

Country Status (13)

Country Link
US (2) US5352708A (de)
EP (1) EP0660716B1 (de)
JP (3) JP3681068B2 (de)
AT (1) ATE209494T1 (de)
AU (1) AU676492B2 (de)
CA (1) CA2144967C (de)
DE (2) DE69331233C5 (de)
DK (1) DK0660716T3 (de)
ES (1) ES2166364T3 (de)
LU (1) LU90957I2 (de)
NL (1) NL300099I2 (de)
PT (1) PT660716E (de)
WO (1) WO1994006433A1 (de)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5834498A (en) * 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US6602900B2 (en) 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US6184250B1 (en) 1993-08-03 2001-02-06 Alcon Laboratories, Inc. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5486540A (en) * 1993-10-28 1996-01-23 Allergan, Inc. Cyclopentane heptanoic or heptenoic acid, 2-arylalkyl or arylalkenyl and derivatives as therapeutic agents
US5545665A (en) * 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
ES2159734T3 (es) * 1995-05-18 2001-10-16 Allergan Sales Inc Derivados 2-heteroarilalquenilicos del acido ciclopentano-heptan(en)oico como agentes terapeuticos para el tratamiento de la hipertension ocular.
US6441047B2 (en) 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US5700835A (en) * 1995-12-22 1997-12-23 Alcon Laboratories, Inc. 3-Oxa-D-prostaglandins for lowering IOP
US5741810A (en) * 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
AU750039B2 (en) 1997-02-04 2002-07-11 Murray A. Johnstone Method of enhancing hair growth
IT1292377B1 (it) * 1997-06-19 1999-02-08 Nicox Sa Composizioni farmaceutiche a base di prostaglandine
IT1292426B1 (it) 1997-06-27 1999-02-08 Nicox Sa Sali nitrati di ace-inibitori
NZ513825A (en) 1999-03-05 2001-09-28 Procter & Gamble C 16 unsaturated FP-selective prostaglandins analogs
IL143477A (en) * 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
US6395787B1 (en) 2000-02-08 2002-05-28 Allergan Sales, Inc. Ocular hypotensive lipids
AU2001241067A1 (en) * 2000-03-09 2001-09-17 Ono Pharmaceutical Co. Ltd. Omega-substituted phenyl-prostaglandin e-alcohols, process for producing the same and drugs containing the same as the active ingredient
US7012090B1 (en) 2000-03-17 2006-03-14 Alcon, Inc. Pyranoindoles for treating glaucoma
US6927233B1 (en) 2000-03-17 2005-08-09 Alcon, Inc. 5ht2 agonists for controlling IOP and treating glaucoma
US20030119846A1 (en) * 2000-03-17 2003-06-26 Collier Jr Robert J. Compounds with 5-ht activity useful for controlling visual field loss
US7005443B1 (en) 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma
US6660870B1 (en) 2000-03-17 2003-12-09 Alcon, Inc. 2-acylaminobenzimidazole derivatives for treating glaucoma
US6806285B1 (en) 2000-03-17 2004-10-19 Alcon, Inc. 5-Hydroxyl indole derivatives for treating glaucoma
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020013294A1 (en) * 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US6291522B1 (en) * 2000-09-27 2001-09-18 Allergan Sales, Inc. Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents
WO2004098807A1 (en) * 2000-11-21 2004-11-18 Barsplice Products, Inc. Method of making steel couplers for joining concrete reinforcing bars
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7842727B2 (en) * 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
KR100437873B1 (ko) 2001-05-08 2004-06-26 연성정밀화학(주) 프로스타글란딘 유도체의 제조방법 및 그의 입체특이적출발물질
US20030212107A1 (en) * 2001-05-10 2003-11-13 Kapin Michael A. R-reliprodil for treating glaucoma
US6531504B2 (en) * 2001-05-17 2003-03-11 Allergan, Inc. Prostanoic acid derivatives as agents for lowering intraocular pressure
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
CA2447156A1 (en) * 2001-06-01 2002-12-12 Alcon, Inc. Novel fused indazoles and indoles and their use for the treatment of glaucoma
MXPA03010806A (es) * 2001-06-01 2004-11-22 Alcon Inc Nuevos analogos de arilaminopropano y su uso para el tratamiento de glaucoma.
MXPA03010807A (es) * 2001-06-01 2004-11-22 Alcon Inc Piranoidazoles y su uso para el tratamiento del glaucoma.
US6713268B2 (en) 2001-06-26 2004-03-30 Allergan, Inc. Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
US6884816B2 (en) * 2001-08-31 2005-04-26 Alcon, Inc. Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) * 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
AU2012261499B2 (en) * 2002-02-04 2016-05-12 Allergan, Inc. Method of enhancing hair growth
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US20040110776A1 (en) * 2002-02-22 2004-06-10 Iok-Hou Pang Use of propentofylline to control intraocular pressure
CA2486303C (en) * 2002-05-22 2013-04-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
CA2487977A1 (en) * 2002-06-06 2003-12-18 Merck Frosst Canada & Co./Merck Frosst Canada & Cie 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
EP1513589B1 (de) 2002-06-06 2010-11-10 Merck Frosst Canada Ltd. 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
US6864282B2 (en) * 2002-08-05 2005-03-08 Allergan, Inc. 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
CA2495917A1 (en) * 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
CN100425241C (zh) * 2002-08-29 2008-10-15 参天制药株式会社 由Rho激酶抑制剂和前列腺素类物质构成的青光眼治疗剂
CN1678302A (zh) * 2002-08-30 2005-10-05 爱尔康公司 取代的5－苯并二氢吡喃－5－基－乙胺化合物及其在治疗青光眼中的用途
CA2505127A1 (en) * 2002-11-08 2004-05-27 James B. Doherty Ophthalmic compositions for treating ocular hypertension
US7196082B2 (en) * 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
JP2006508120A (ja) * 2002-11-12 2006-03-09 アルコン，インコーポレイテッド 眼の変性疾患を処置するためのヒストンデアセチラーゼインヒビター
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
JP4314433B2 (ja) 2002-11-18 2009-08-19 参天製薬株式会社 Ｒｈｏキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
EP1567142A4 (de) * 2002-11-20 2005-12-14 Errant Gene Therapeutics Llc Behandlung von lungenzellen mit histondeacetylase-hemmern
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
JP2006511556A (ja) * 2002-12-13 2006-04-06 アルコン，インコーポレイテッド 新規のベンゾピラン類似体及び緑内障の治療のためのそれらの使用
US20040216749A1 (en) * 2003-01-23 2004-11-04 Hosheng Tu Vasomodulation during glaucoma surgery
JP2007521296A (ja) * 2003-07-01 2007-08-02 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧の治療のための眼科用組成物
EP1664011A4 (de) * 2003-09-02 2009-02-25 Merck & Co Inc Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
WO2005025568A1 (en) * 2003-09-04 2005-03-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
MXPA06002515A (es) * 2003-09-04 2006-06-20 Merck & Co Inc Composiciones oftalmicas para el tratamiento de la hipertension ocular.
DE602004023106D1 (de) * 2003-11-07 2009-10-22 Senju Pharma Co Pharmazeutische zusammensetzung mit prostaglandin
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
WO2005053688A1 (en) * 2003-11-26 2005-06-16 Alcon, Inc. Substituted furo[2,3-g] indazoles for the treatment of glaucoma
TW200520760A (en) * 2003-12-15 2005-07-01 Alcon Inc Substituted [1,4] oxazino [2,3-g] indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
PT1740164E (pt) * 2004-04-26 2008-10-21 Alcon Inc Estatinas para o tratamento da hipertensão ocular e glaucoma
CN1988903A (zh) 2004-07-20 2007-06-27 默克公司 用于治疗高眼压症的眼用组合物
WO2006041875A1 (en) 2004-10-06 2006-04-20 Allergan, Inc. Novel prostamides for the treatment of glaucoma and related diseases
EP1802299A2 (de) * 2004-10-13 2007-07-04 Merck & Co., Inc. Ophthalmische zusammensetzungen zur behandlung von augenhochdruck
AU2005295997A1 (en) * 2004-10-13 2006-04-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
EP1817020A4 (de) * 2004-11-08 2012-11-21 Errant Gene Therapeutics Inc Inhibitoren der histondeacetylase
WO2006062839A1 (en) * 2004-12-08 2006-06-15 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
WO2010102078A1 (en) 2009-03-04 2010-09-10 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
PL1864666T3 (pl) 2005-03-31 2013-02-28 Agc Inc Czynnik ochronny dla komórki neuronalnej siatkówki zawierający jako składnik aktywny pochodną prostaglandyny F2 alfa
EP1870099A4 (de) 2005-04-13 2008-07-16 Ube Industries Schutzmittel für retinale nervenzellen mit einem indazol-derivat als wirkstoff
WO2007002670A2 (en) * 2005-06-28 2007-01-04 Bausch & Lomb Incorporated Method of lowering intraocular pressure
US20070015838A1 (en) * 2005-07-14 2007-01-18 Allergan, Inc. Cyclopentane n-lower alkyl heptenamide-5-cis-2-(3alpha-hydroxy-5-phenylpentyl)-3, 5-dihydroxy, [1alpha, 2beta, 3alpha, 5alpha] compounds as agents for lowering intraocular pressure
EP1912957A4 (de) * 2005-08-03 2009-05-13 Merck Frosst Canada Ltd Ep4-rezeptor-agonist, zusammensetzungen und methoden
TW200744567A (en) * 2005-09-23 2007-12-16 Alcon Inc Phenylethylamine analogs and their use for treating glaucoma
CA2624837A1 (en) * 2005-10-14 2007-04-26 Alcon, Inc. Method for treating primary and secondary forms of glaucoma
US20080125406A1 (en) * 2005-10-14 2008-05-29 Robin Alan L Method for Treating Primary and Secondary Forms of Glaucoma
AU2006311942B2 (en) * 2005-11-03 2012-11-22 Allergan, Inc. Prostaglandins and analogues as agents for lowering intraocular pressure
US20090197930A1 (en) * 2006-02-02 2009-08-06 Kenji Yoshida Eyedrops
EP2004193A2 (de) * 2006-03-13 2008-12-24 Merck & Co., Inc. Ophthalmische zusammensetzungen zur behandlung von augenhochdruck
JP2009541219A (ja) * 2006-06-12 2009-11-26 メルク エンド カムパニー インコーポレーテッド 高眼圧治療のための眼科組成物
US7429669B2 (en) * 2006-06-20 2008-09-30 Allergan, Inc. Therapeutic compounds
WO2008008718A2 (en) * 2006-07-11 2008-01-17 Allergan, Inc. Cyclopentane derivatives as antiglaucoma agents
US20080015219A1 (en) * 2006-07-11 2008-01-17 Allergan, Inc. Therapeutic compounds
IL177762A0 (en) * 2006-08-29 2006-12-31 Arieh Gutman Bimatoprost crystalline form i
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
BRPI0717093A2 (pt) * 2006-09-28 2013-11-26 Alcon Res Ltd Composições farmacêuticas aquosas autopreservadas
US20090048146A1 (en) * 2006-12-21 2009-02-19 Alcon, Inc. Use of agents that upregulate crystallin expression in the retina and optic nerve head
UY30883A1 (es) 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
EP2125773B1 (de) * 2007-02-01 2011-01-26 Allergan, Inc. Thiophenderivate als medikamente zur behandlung von okularer hypertonie
WO2009006370A1 (en) * 2007-07-03 2009-01-08 Allergan, Inc. Therapeutic substituted cyclopentanes for reducing intraocular pressure
US20090018204A1 (en) * 2007-07-13 2009-01-15 Brinkenhoff Michael C Composition and method for enhancing hair growth
US20090232763A1 (en) * 2008-03-17 2009-09-17 Kabra Bhagwati P Aqueous pharmaceutical compositions containing borate-polyol complexes
AR076731A1 (es) * 2008-05-09 2011-07-06 Pfizer Prostamidas donadoras de oxido nitrico, uso de los mismos y composiciones farmaceuticas
EP2135860A1 (de) 2008-06-20 2009-12-23 Sandoz AG Verbesserter Herstellungsverfahren für Bimatoprost
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20100204335A1 (en) * 2008-12-01 2010-08-12 Allergan, Inc. Kit and composition for eyelash growth
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
WO2010112615A1 (en) 2009-04-03 2010-10-07 Dsm Ip Assets B.V. Lysine derivatives functionalised with lipids
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
TWI489997B (zh) * 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
KR20120081227A (ko) 2009-11-02 2012-07-18 샹하이 테크웰 바이오파마슈티컬 컴퍼니, 리미티드 비마토프로스트 결정 및 그의 제조방법과 용도
EP2498783B1 (de) * 2009-11-09 2018-08-22 Allergan, Inc. Zusammensetzungen und verfahren zur stimulation des haarwuchses
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
WO2011057269A2 (en) 2009-11-09 2011-05-12 Allergan, Inc. Compositions for enhancing hair growth
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
US8783923B2 (en) * 2010-03-18 2014-07-22 Chung Yuan Christian University Auto lamp structure
WO2011127064A2 (en) 2010-04-06 2011-10-13 Allergan, Inc. Sustained-release reservoir implants for intracameral drug delivery
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
EP2598118B1 (de) 2010-07-29 2018-09-05 Allergan, Inc. Bimatoprost- und timolollösungen ohne konservierungsstoffe
EP2600825B1 (de) 2010-08-02 2018-12-12 Ac Patent Holding Inc. Verfahren zum locekn von Haar
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
CN103747775A (zh) 2011-01-31 2014-04-23 阿勒根公司 促进毛发生长的方法
TW201235040A (en) 2011-02-04 2012-09-01 Kowa Co Drug therapy for preventing or treating glaucoma
JP5885271B2 (ja) 2011-02-14 2016-03-15 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ビマトプロストのエステル誘導体の組成物および方法
HUE033642T2 (en) 2011-06-02 2017-12-28 Chinoin Zrt A new method for the destruction of prostaglandin amides
US9987213B2 (en) 2012-06-13 2018-06-05 Edward Dunne Corboy, JR. Topical dihydrotestosterone (DHT) for promoting hair growth—containing formulations
WO2014066775A1 (en) 2012-10-26 2014-05-01 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
EP2968093A1 (de) 2013-03-14 2016-01-20 Allergan, Inc. Topische zusammensetzungen mit bimatoprost und verfahren zur anregung des haarwuchses damit
CA2906123C (en) 2013-03-15 2021-11-30 Allergan, Inc. Prostamide-containing intraocular implant
EP3091985A4 (de) 2014-01-10 2017-11-29 Manistee Partners LLC Behandlung von migränen
EA034839B1 (ru) 2014-10-20 2020-03-26 Сентисс Фарма Прайвет Лимитед Офтальмологический раствор
CA2968926C (en) 2014-11-25 2023-01-17 Izhar Halahmi Compositions and methods for delivering a bio-active agent or bio-active agents
SG11201705767PA (en) 2015-01-13 2017-08-30 Univ Kyoto Agent for preventing and/or treating amyotrophic lateral sclerosis
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
EP3235810A1 (de) 2016-04-19 2017-10-25 Gentec, S.A. Verfahren zur herstellung von bimatoprost
RU2718744C2 (ru) * 2018-05-17 2020-04-14 Общество с ограниченной ответственностью "Гурус БиоФарм" Производные простагландина F2альфа для снижения внутриглазного давления

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE37602B1 (en) * 1971-05-11 1977-08-31 Ici Ltd Cyclopentane derivatives
GB1402035A (en) * 1972-12-07 1975-08-06 Ici Ltd Cyclopentane derivatives
GB1451798A (en) * 1973-08-02 1976-10-06 Ici Ltd Prostanoic acid derivatives
US4183870A (en) * 1974-01-26 1980-01-15 May & Baker Limited Cyclopentane derivatives
GB1486832A (en) * 1974-08-05 1977-09-28 Ici Ltd Prostanoic acid derivatives
NL7605381A (nl) * 1975-05-26 1976-11-30 Schering Ag Werkwijze voor het bereiden van prostaanderi- vaten en werkwijze voor het bereiden van een geneesmiddel met prostaglandinewerking.
US4128577A (en) * 1975-12-29 1978-12-05 The Upjohn Company 15-Methyl- and 16-phenoxy-PGF2 α, amides
US4055602A (en) * 1976-01-08 1977-10-25 The Upjohn Company 2-Decarboxy-2-hydroxy-methyl-5-oxa-17-phenyl-18,19,20-trinor-PGF-analogs
US4091207A (en) * 1976-04-22 1978-05-23 Pfizer Inc. Prostaglandin intermediate including oxathio heterocyclic ring
IL51877A (en) * 1976-06-01 1981-09-13 Carlo Erba Sa -nor-16-benzyl or phenoxy-13,14-dehydro-prostaglandins and process for their preparation
JPS53121742A (en) * 1977-03-31 1978-10-24 Ono Pharmaceut Co Ltd Prostaglandin analogous compounds and process for their preparation
DE2715838A1 (de) * 1977-04-05 1978-10-19 Schering Ag Neue prostanderivate und verfahren zu ihrer herstellung
US4163758A (en) * 1977-09-09 1979-08-07 Sagami Chemical Research Center 2-Nitroethylcyclopentane compounds and process for preparing the same
US4171331A (en) * 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
JPS5583775A (en) * 1978-12-20 1980-06-24 Toray Ind Inc 13,14-epoxyprostaglandin
US4275074A (en) * 1979-03-09 1981-06-23 Graham J. Dobbie Catecholamine treatment of ocular hypertension
US4292445A (en) * 1980-04-28 1981-09-29 The Upjohn Company Amide and sulfonamide derivatives of 2-decarboxy-2-aminomethyl-PG-type compounds
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
DE3371199D1 (en) * 1982-08-24 1987-06-04 Teijin Ltd Novel 6-nitroprostaglandin derivatives, process for production thereof, and use thereof
JPS59190964A (ja) * 1983-04-15 1984-10-29 Ono Pharmaceut Co Ltd 新規なプロスタグランジンｄ類似化合物
US4824857A (en) * 1986-05-16 1989-04-25 Yasumasa Goh Use of prostaglandin D2 -active substances
ATE420857T1 (de) * 1988-09-06 2009-01-15 Pfizer Health Ab Prostaglandin-derivate zur behandlung von glaukom und ocularer hypertension
US5034413A (en) * 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US4994274A (en) * 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
TW249226B (de) * 1990-04-04 1995-06-11 Aderk Ueno Kk
US5270049A (en) * 1990-11-09 1993-12-14 Allergan, Inc. 2-decarboxyl-2-aminoalkyl-prostaglandins as ocular hypotensives
WO1992008464A1 (en) * 1990-11-15 1992-05-29 Tanabe Seiyaku Co. Ltd. Substituted urea and related cell adhesion modulation compounds
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents

Also Published As

Publication number Publication date
EP0660716A1 (de) 1995-07-05
DE10299037I2 (de) 2004-09-23
WO1994006433A1 (en) 1994-03-31
US5607978A (en) 1997-03-04
LU90957I2 (fr) 2003-04-30
JPH08501310A (ja) 1996-02-13
JP2004346080A (ja) 2004-12-09
AU676492B2 (en) 1997-03-13
CA2144967A1 (en) 1994-03-31
US5352708A (en) 1994-10-04
JP3681068B2 (ja) 2005-08-10
NL300099I1 (nl) 2002-11-01
ATE209494T1 (de) 2001-12-15
DE69331233D1 (de) 2002-01-10
ES2166364T3 (es) 2002-04-16
PT660716E (pt) 2002-05-31
EP0660716B1 (de) 2001-11-28
AU4852693A (en) 1994-04-12
DE69331233T2 (de) 2002-06-27
DK0660716T3 (da) 2002-04-02
JP2011052014A (ja) 2011-03-17
DE69331233C5 (de) 2014-06-18
NL300099I2 (nl) 2003-03-01
CA2144967C (en) 2003-11-11

Similar Documents

Publication Publication Date Title
DE10299037I1 (de) 2-Zykloakyl-oder Arylalkylderivate von nicht-Saeure Zyklopentane-Heptanoic-Saeure
ITFI920058A0 (it) Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
PT1041990E (pt) Composicao para o tratamento de doencas respiratorias e doencas de pele, compreendendo pelo menos um antagonista de leucotrieno e pelo menos um anti-histaminico
DE60121857D1 (de) Arzneimittelzusammensetzung mit verzögerter Wirkstoffabgabe
NO970042D0 (no) 2-£(Dihydro)pyrazolyl-3'-oksymetylen|-anilider, fremgangsmåte til fremstilling og anvendelse derav
BR9811827A (pt) Preparações de aerossol aquosas contendo macromoléculas biologicamente ativas e processo para a produção de aerossóis correspondentes
CY1104989T1 (el) Μεθοδος παρασκευης αιθυλεστερος του (-)-(2r,4s)-4-[(3,5-δiς-tpiφθopomeθyλo-βενζυλο)-μεθοξυκαρβονυλαμινο]-2-αιθυλο-6-τριφθορο-μεθυλο-3,4-διϋδρο-2η-κινολινο-1-καρβοξυλικου οξεος
BR9306848A (pt) Anel polimérico dividido para introdução no estroma
BR9707892A (pt) Derivados de ácido 2-heteroalrialquenil ciclopentano hepta(EN)óico como agentes terapêuticos
EE03202B1 (et) Intravaginaalne manustussüsteem ja selle valmistamismeetod
ATE254891T1 (de) Stent zur transluminalen implantation
NL300101I2 (nl) Topisch ofthalmische formuleringen die olopatadinebevatten voor het
DE60331638D1 (de) Keratin-netzwerke enthaltende wundverbände für gewebedefekte
BR9712100A (pt) Intermediários e processo para preparar olanzapina.
CA2316985A1 (en) Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
WO1998039293A3 (en) 13-thia prostaglandins for use in glaucoma therapy
BR9807145A (pt) 2-metoxiimino-2-(piridiniloximetil) fenilacetamidas com derivados de ácido carboxìlico no anel de piridina como fungicidas.
DK0665741T3 (da) Topiske, oftalmiske, farmaceutiske bærere
BR9812085A (pt) "método para a sìntese de derivados de quinolina"
TR199600348A2 (tr) Kükürtlü boyalar,bunlarin imali ve kullanimi.
CA2329427A1 (en) Truss enhanced bridge girder
IT1255749B (it) Bassi polimeri dell'n-vinilpirrolidone monofunzionalizzati ad un estremo per la preparazione di coniugati con enzimi, polipeptidi, farmaci
BR9813037A (pt) Composto, processo para sua preparação, uso do mesmo, preparação farmacêutica, e, combinação desta com pelo menos uma outra substância ativa
WO1999011249A3 (en) Use of endipalene in the treatment of psoriasis
WO2001089493A3 (en) Compositions containing a benzamide disulfide derivative for treating allergic diseases